Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance)

Authors

Timothy C. Hardman (ORCID: https://orcid.org/0000-0002-1417-9019)
Dadong Zhang (ORCID: https://orcid.org/0000-0001-6419-8886)
Alexander B. Sibley (ORCID: https://orcid.org/0000-0003-4552-1865)
Lunden Simpson (ORCID: https://orcid.org/0000-0002-7556-1078)
Marissa R. Lee (ORCID: https://orcid.org/0000-0001-7188-9933)
Kouros Owzar (ORCID: https://orcid.org/0000-0002-3340-1287)
Jeffrey R. Marks (ORCID: https://orcid.org/0000-0002-2054-5468)
Jeff Sheng
Tina J. Hieken (ORCID: https://orcid.org/0000-0002-4277-8692)
Elissa R. Price (ORCID: https://orcid.org/0000-0001-9572-7795)
Isabelle Bedrosian (ORCID: https://orcid.org/0000-0002-8775-8361)
Yanwan Dai (ORCID: https://orcid.org/0000-0002-4485-4396)
Eui-Hyoung Hwang (ORCID: https://orcid.org/0000-0003-0460-3194)
Allison Hall
Yunn-Yi Chen

Institutions

The University of Texas MD Anderson Cancer Center (US)
University of British Columbia (CA)
Duke University (US)
University of California, San Francisco (US)
Duke Institute for Health Innovation (US)
Mayo Clinic in Arizona (US)
Duke Medical Center (US)
Alliance Data (United States) (US)

Publication Details

Journal: Breast Cancer Research
Published: 2025-02-20
DOI: https://doi.org/10.1186/s13058-025-01963-5
Primary Topic: Estrogen and related hormone effects
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Breast Cancer Research Foundation

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance)

Timothy C. Hardman, Dadong Zhang, Alexander B. Sibley, Lunden Simpson et al.

Feb 20, 2025

Breast Cancer Research

Estrogen and related hormone effects

article

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance)

Timothy C. Hardman, Dadong Zhang, Alexander B. Sibley, Lunden Simpson, Marissa R. Lee, Kouros Owzar, Jeffrey R. Marks, Jeff Sheng, Tina J. Hieken, Elissa R. Price, Isabelle Bedrosian, Yanwan Dai, Eui-Hyoung Hwang, Allison Hall, Yunn-Yi Chen

February 20, 2025article en

Abstract

No abstract available for this paper.

Breast Cancer ResearchVol. 27(1)

The University of Texas MD Anderson Cancer Center (US), University of British Columbia (CA), Duke University (US), University of California, San Francisco (US), Duke Institute for Health Innovation (US), Mayo Clinic in Arizona (US), Duke Medical Center (US), Alliance Data (United States) (US)

Breast Cancer Research Foundation

Good health and well-being

Openalex Percentile: Top 96%

Estrogen and related hormone effects

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance) — Timothy C. Hardman, Dadong Zhang, et al. · Breast Cancer Research (2025) | TGRS Research Map | TGRS